Bristol Myers (BMY) announced that a late-stage study on orally-administered Zeposia (ozanimod) in Crohn’s disease (CD) indication failed to achieve its primary endpoint.This late-stage study was the first of the two induction studies in the phase III YELLOWSTONE clinical program, which evaluated Zeposia in 600 adult patients with moderate to severe active CD over a 12-week treatment period. Initial results from the study showed that treatment with Zeposia failed to meet the primary endpoint of clinical rem ...

Biotech is an industry full of opportunity. It’s also known as one of the riskiest sectors to invest in. Why is this the case? Well, many of these companies are very small and focused on researching new drugs. These drugs, being their products, are thus in development and thus the future revenue is not assured. The future revenue hinges on successful FDA approvals and the ability to actually sell the drug. As such, this industry is known for companies that tank 50% in just days following poor clinical resul ...

股价表现 - Bristol Myers Squibb (BMY) 最近的股价为 $51.59，较前一交易日收盘价下跌了 -0.56% [1] - Bristol Myers Squibb 公司股票在过去一个月内上涨了 1.91%，超过了医疗行业的增长率 [2] 财务表现 - Bristol Myers Squibb 公司将于 2024 年 4 月 25 日发布财报，预计每股收益为 $1.53，较去年同期下降了 25.37% [3] - 分析师预测 Bristol Myers Squibb 公司的营收将从去年同期的 $11.46 亿美元上涨 1.11% [4] - Zacks Consensus Estimates 预测 Bristol Myers Squibb 公司全年每股收益为 $6.61，营收为 $46.11 亿美元，较去年分别下降了 11.98% 和上涨了 2.45% [5] 评级和排名 - 近期分析师对 Bristol Myers Squibb 公司的估值进行了修改，这通常代表着近期业务趋势的变化 [6] - Zacks Rank 系统显示 Bristol Myers Squibb 公司目前的排名为 4 (卖出)，过去一个月 Zacks Consensus EPS 估计上涨了 0.02% [8] 行业比较 - Bristol Myers Squibb 公司目前的 Forward P/E 比率为 7.85，低于行业的 24.51 [9] - BMY 公司的 PEG 比率为 1.57，略高于行业平均值 [10] - 医疗 - 生物医学和遗传学行业属于医疗部门，目前排名在所有 250+ 个行业的前 32% [11] - Zacks Industry Rank 显示，评级较高的行业通常表现优于评级较低的行业 [12]

Bristol Myers (BMY) announced that the European Commission (EC) has approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma.The therapy is now approved in the European Union (EU) in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.Abecma is already approved in the EU, Switzerland, Japan, the United Kingdom and Israel for adult patients with triple-class exposed relapsed or refractory multiple myeloma after three to four or more prior lines of ...

PRINCETON, N.J.--(BUSINESS WIRE)--Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “SO, Have You Found It?” campaign. This initiative spotlights the resilience of around two million Americans with moderate to severe plaque psoriasis, aiming to amplify their voices, underscoring the strength of their inner vibe, the “it” factor that makes someone uniquely them.i The campaign signifies a shift in dialogue from the challenges associated with ...

FDA审批 - Bristol Myers Squibb (BMY) 和合作伙伴 2seventy bio, Inc (TSVT) 宣布，FDA 肿瘤药物咨询委员会 (ODAC) 投票支持 Abecma (idecabtagene vicleucel) 对于三类药物暴露的复发性或难治性多发性骨髓瘤 (RRMM) 患者的益处/风险概况[1] - Abecma 是一种嵌合抗原受体 (CAR) T细胞疗法，已经适用于接受过四种或更多先前治疗线路的成年患者，包括免疫调节剂、蛋白酶体抑制剂和抗CD38单克隆抗体[2] - ODAC 中的 8 名成员中有 12 名支持 Abecma，称其在早期治疗中对三类药物暴露的多发性骨髓瘤患者展示了有利的益处/风险概况[3] - 基于 KarMMa-3 研究的结果，包括总生存期 (OS) 的关键次要终点，ODAC 对 Abecma 投票持有有利态度[4]

PureTech Health plc收购Karuna Therapeutics, Inc. - PureTech Health plc宣布完成了其子公司Karuna Therapeutics, Inc.的收购交易，被Bristol Myers Squibb以每股330美元的价格收购，总股权价值约为140亿美元[1] - KarXT有望成为50年来首个为精神分裂症患者提供新治疗机制的药物，对于需要新疗法的数百万精神分裂症患者具有巨大潜力[2] - PureTech在Karuna的持股比例约为2.3%，预计交易完成后将获得约2.93亿美元的总收益，同时保留了在达到某些监管批准里程碑时获得里程碑付款的权利[3]

宝姿斯公司收购Karuna Therapeutics, Inc. - 宝姿斯公司成功完成对Karuna Therapeutics, Inc.的收购，Karuna现在是宝姿斯的全资子公司[1] - 宝姿斯公司通过此次交易获得了KarXT（xanomeline-trospium），一种具有新颖作用机制和差异化疗效和安全性概况的抗精神病药物，以及Karuna的早期和临床前管线[2] 交易影响 - 此次交易预计将对宝姿斯公司2024年的非GAAP摊薄每股收益产生约30美分的稀释效应，主要来自最近完成的新债务发行[3] - 此次交易将作为资产收购进行会计处理，导致约120亿美元的一次性、不可抵扣的收购前研发费用（Acquired IPR&D）支出，预计将影响2024年第一季度和全年的GAAP和非GAAP每股收益约5.93美元[4]

Perspective Therapeutics, Inc.与Bristol Myers Squibb合作 - Perspective Therapeutics, Inc.将赞助和资助组合研究，Bristol Myers Squibb将提供nivolumab供研究使用[2] - Perspective Therapeutics, Inc.的首席医疗官Markus Puhlmann表示，对[212Pb]VMT01与nivolumab的联合治疗效果充满潜力[3] 潜在治疗效果 - [212Pb]VMT01与免疫检查点抑制剂的组合在PD-1/CTLA-4耐药的前临床黑色素瘤模型中表现出潜力[4]

Abecma CAR T细胞疗法 - 美国食品药品监督管理局（FDA）肿瘤药品咨询委员会（ODAC）对Abecma在三类药物暴露后复发或难治性多发性骨髓瘤患者中表现出有利的风险/效益比例进行了积极投票[1] - Abecma是一种CAR T细胞疗法，通过识别和结合多发性骨髓瘤细胞表面的B细胞成熟抗原（BCMA），导致CAR T细胞增殖、细胞因子分泌和随后对表达BCMA的细胞的溶解杀伤[4] - Abecma已在日本和瑞士获得批准，用于接受至少两种先前疗法（包括免疫调节剂、蛋白酶体抑制剂和抗CD38抗体）的复发和/或难治性多发性骨髓瘤患者，使其成为首个获得批准用于早期疗法线的CAR T细胞疗法[3] ABECMA治疗注意事项 - ABECMA治疗可能导致患者出现继发性恶性肿瘤，建议终身监测[30][31] - ABECMA治疗后8周内患者可能出现神经事件，需避免驾驶和操作危险机械[31] - ABECMA治疗可能引起的常见非实验室不良反应包括CRS、感染、疲劳、肌肉骨骼疼痛等[32]